First case report of immune checkpoint inhibitor therapy to treat secretory carcinoma.

ABSTRACT: Secretory carcinoma (SC) is a newly defined and exceedingly rare pathologic subtype of lung cancer. We present a case of SC that was initially misdiagnosed as stage IIIB (cT2aN3M0) invasive mucinous adenocarcinoma harboring a programmed cell death ligand 1 tumor proportion score of 10% and an ETV6-MET fusion gene. The patient received five cycles of toripalimab and pemetrexed plus carboplatin at a local hospital without treatment-related adverse events. Radiologic evaluations prior to third- and fifth-cycle immunochemotherapy indicated that the best response was stable disease. The patient was subsequently reclassified as having stage IB (cT2aN0M0) primary pulmonary malignancy after invasive N staging at our institution, and the primary tumor and mediastinal lymph nodes were

SUBMITTER: Yu X 

PROVIDER: S-EPMC12314235 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature